Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.
Whether non-selective beta blockers (NSBBs) are deleterious in patients with end stage cirrhosis and refractory ascites or not is debated with contrasting results. We hypothesized that only a subset of patients with impaired cardiac performance could be at increased risk of mortality on the waiting list for liver transplantation if receiving NSBBs. The study included 584 consecutive patients with cirrhosis evaluated for transplantation between 1999 and 2014. All patients had right heart catheterization with hemodynamic measurements at evaluation. Fifty percent received NSBBs. Refractory ascites was present in 33%. Cardiac performance was assessed by left ventricular stroke work index (LVSWI). Waitlist mortality without liver transplantation was explored using competing risk analysis. LVSWI was significantly lower in patients with refractory ascites. In multivariate analysis using competing risk, refractory ascites, NSBBs and LVSWI were associated with waiting list mortality in the whole population, with a statistically significant interaction between NSBBs and LVSWI. The most discriminant value of LVSWI was 64.1 g.m/m2. In the final model, refractory ascites (SHR: 1.52 (1.01-2.28); P=0.0083) and treatment by NSBBs with LVSWI < 64.1 g.m/m2 (SHR: 1.96 (1.32-2.90); P=0.0009) were significantly associated with waiting list mortality, taking into account serum sodium and the MELD score. This study suggests that compromised cardiac performance is more common in patients with refractory ascites and that NSBBs are deleterious in cirrhosis patients with compromised cardiac performance. These results highlight the prognostic value of cardiac function in patients with end stage cirrhosis. There are still controversies concerning the impact of non-selective beta-blockers on the outcome in patients with decompensated cirrhosis, especially those with refractory ascites. In this study based on 584 cirrhotic patients evaluated for transplantation and who had right heart catheterization, we have shown that global cardiac performance measured by left ventricular stroke work index is lower in patients with refractory ascites. Administration of non-selective beta-blockers in patients with compromised cardiac performance may increase waiting list mortality. These results highlight the prognostic value global cardiac performance in patients with end stage cirrhosis.